Here, we review the role of GLP-1 and the actions of associated therapies on glucose metabolism, the gutrenal axis, classical renal risk factors, and renal end points in randomized controlled trials of GLP-1 receptor agonists and DPP-4 inhibitors in patients with T2DM
DOI Henkin Y, Oberman A, Hurst DC, Segrest JP
Avoidance of hypoglycemia, especially in comparison with sulphonylureas and insulin, is likely to be the major advantage of these newer treatments for type 2 diabetes
Phase 3 studies are underway to confirm the full safety profile of retatrutide
Only some people can use GLP-1 for the long term, so what if an established exercise routine during GLP-1 use could result in maintained weight loss